Conceptio › Archive › HAL (France)
HAL (France)open access

TARGET: A phase I/II open-label multicenter study to assess safety and efficacy of fexagratinib in patients with relapsed/refractory FGFR fusion-positive glioma

Alberto Picca et al.
HAL (France) · Papers · License: Open Access
Open Source ↗
clinical-trialglioblastomaglioma
Glioblastoma, 2, FGFR3–TACC3, Fexagratinib, Glioma, 1, Clinical trial, 0
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗
Record · ID 235083
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.